Loading...
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and CDK4/6 inhibitors are FDA-approved for treating patients with metastatic breast cancer. However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive. Here, we report i...
Saved in:
| Published in: | Angew Chem Int Ed Engl |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678623/ https://ncbi.nlm.nih.gov/pubmed/30802347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201901336 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|